Tong Ren Tang Technologies (1666) Fundamentals 2026 — P/E 10.0x, Revenue Analysis | SniperIQ
Tong Ren Tang Technologies (1666) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of HK$4.5B, trading at HK
Tong Ren Tang Technologies (1666) has a market capitalization of approximately HK$4.5B, trading at HK
Tong Ren Tang Technologies's trailing twelve-month P/E ratio is 10.0x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Tong Ren Tang Technologies runs a net profit margin of 6.1%, a gross margin of 38.0%, and an operating margin of 12.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Tong Ren Tang Technologies reported revenue of ¥6.5B for fiscal year 2025, with net income of ¥396M and earnings per share (EPS) of 0.31. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Tong Ren Tang Technologies offers a trailing dividend yield of about 5.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Tong Ren Tang Technologies carries a debt-to-equity ratio of 0.30x and a current ratio of 5.72x, with a market beta of 0.77. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tong Ren Tang Technologies (1666) the key facts are: market cap HK$4.5B, P/E 10.0x, revenue ¥6.5B, 52-week range 3.07-5.52. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Get Tong Ren Tang Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.